Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mercy Gohil

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Immunity|September 30, 2023
Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cellsSangya Agarwal, M Angela Aznar, Andrew J Rech, et al.
Research Square|February 12, 2026
Cell-derived Nanoparticles Provide a Robust Platform to Manufacture Therapeutic T cellsJames Riley, Mosha Deng, Tanishk Sinha, et al.
Nature Medicine|February 6, 2021
Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemiaJoseph A Fraietta, Simon F Lacey, Elena J Orlando, et al.
Nature Medicine|May 2, 2018
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemiaJoseph A Fraietta, Simon F Lacey, Elena J Orlando, et al.
Nature|June 1, 2018
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cellsJoseph A Fraietta, Christopher L Nobles, Morgan A Sammons, et al.
Nature Medicine|March 22, 2022
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trialVivek Narayan, Julie S Barber-Rotenberg, In-Young Jung, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Immunity|September 30, 2023
Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cellsSangya Agarwal, M Angela Aznar, Andrew J Rech, et al.
Research Square|February 12, 2026
Cell-derived Nanoparticles Provide a Robust Platform to Manufacture Therapeutic T cellsJames Riley, Mosha Deng, Tanishk Sinha, et al.
Nature Medicine|February 6, 2021
Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemiaJoseph A Fraietta, Simon F Lacey, Elena J Orlando, et al.
Nature Medicine|May 2, 2018
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemiaJoseph A Fraietta, Simon F Lacey, Elena J Orlando, et al.
Nature|June 1, 2018
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cellsJoseph A Fraietta, Christopher L Nobles, Morgan A Sammons, et al.
Nature Medicine|March 22, 2022
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trialVivek Narayan, Julie S Barber-Rotenberg, In-Young Jung, et al.
Pageof 2